BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Infectious Diseases Disease Analysis: Pneumococcal Vaccines

December 10, 2020

The value of the pneumococcal vaccines market will steadily grow over the forecast period due to increasing elderly populations across France, Spain, and the US, alongside continued short-term price increases in the lucrative US market. A brief period of increased growth is expected with the anticipated launch of the 20-valent vaccine, PF-06482077, which may replace Prevnar 13 and Pneumovax 23 in adults (from June 2021) and Prevnar 13 in infants (from H1 2023). Overall, the biggest opportunity for short-term growth within the pneumococcal vaccines market is associated with increasing vaccination rates within the elderly in the US and Italian markets; however, the 2019 reversal of the original 2014 ACIP recommendation for Prevnar 13’s use in the elderly population will hamper its growth in the US.

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Pneumococcal (Streptococcus pneumoniae) Vaccines (Antibacterial)
Back to the top Back to the top